Martin S. Tallman, MD, Chief of Leukemia Service, Memorial Sloan Kettering Cancer Center, joins the Samuel Waxman Cancer Research Foundation’s Scientific Advisory Board

Martin S. Tallman, M.D.

 

 

New York, NY, March 7, 2018 – The Samuel Waxman Cancer Research Foundation (SWCRF) today announced that Martin S. Tallman, M.D., Chief of Leukemia Service at Memorial Sloan Kettering Cancer Center (MSK), has joined its Scientific Advisory Board (SAB). Dr. Tallman, who continues his role at MSK, will join his fellow SAB members at the SWCRF Breakthroughs Scientific Review and Symposium on April 29 and April 30, which marks the annual evaluation of SWCRF funded research programs. 

“It is our great pleasure to welcome Dr. Martin Tallman to our distinguished group of SAB members,” said Dr. Samuel Waxman, M.D., Founder and CEO of the Samuel Waxman Cancer Research Foundation. “He is a longtime friend to the SWCRF and brings an expertise that will greatly enrich our scientific brain trust. We are looking forward to his contributions to our annual review process.” 

The SWCRF SAB, together with the Foundation’s scientific leaders, evaluates grant proposals submitted by scientists with NCI-approved research programs. The board includes Lorraine Gudas, Ph.D., Chair of Pharmacology at Weill Cornell Medical Center, Robert A. Hromas, M.D., F.A.C.P., Dean of the Joe R. and Teresa Lozano Long School of Medicine at University of Texas Health, Ramon Parsons, M.D., Ph.D., Director of the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, Nancy Speck, Ph.D., Professor of Cell and Developmental Biology at the University of Pennsylvania, and Hua Yu, Ph.D., Professor of Cancer Immunotherapeutics and Tumor Immunology, City of Hope NCI Comprehensive Cancer Center. 

The SWCRF’s scientific leadership includes Samuel Waxman, M.D., Founder and CEO, Jonathan D. Licht, M.D., SWCRF Chief Scientific Officer, and Alan G. Rosmarin, M.D., SWCRF Chief Mission Officer. 

The SWCRF Breakthroughs Scientific Review and Symposium brings together the Institute Without Walls, a network of the foundation’s funded scientists working collaboratively throughout the United States and abroad on research projects that identify and correct abnormal gene function that causes cancer. This research is the basis for developing minimally toxic treatments for patients. The network includes scientists from leading cancer research institutions, including Dana-Farber Cancer Institute, Johns Hopkins University, Memorial Sloan Kettering Cancer Center, the Icahn School of Medicine at Mount Sinai and Weill Cornell Medical Center, among many others.